Companies: 10,795·Total market cap: $144.5T

Revelation Biosciences, Inc.

Revelation Biosciences, Inc.

REVBNASDAQHealthcare● Active

$1.03

+$0.02(+1.49%)

Market Cap$4006130

P/E Ratio—

52W High$12.88

52W Low$0.875

Avg Volume71K

Open$1.00

Beta-0.08

Net Income Financials Revenue

Revelation Biosciences, Inc. (REVB) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

REVB · net income · updated Jun 9, 2026

Core profitability metrics

REVB · net income · margin · TTM · CAGR

Net income was −$8.9M for FY2025 (fiscal year ending 2025-12-31), up 40.7% year-over-year. Net profit margin was —.

FY2025 Net Income−$8.9M▲ +40.7% YoY

Trailing 12M (TTM)—trailing 4 quarters sum

Net Profit Margin——

YoY Change+40.7%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · REVB net income history · REVB profit margin

Annual net income data

REVB · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$8.9M▲ +40.7%—$0

FY2024Loss−$15.0M▼ 12405.6%—$0

FY2023Loss−$120,254▲ +98.9%—$0

FY2022Loss−$10.8M▲ +9.7%—$0

FY2021Loss−$12.0M▼ 635.2%—$0

Net income vs peers (Healthcare)

REVB vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

Johnson & Johnson

$26.80B+90.6%28.5%

Eli Lilly and Company

$20.64B+94.9%31.7%

UnitedHealth Group Incorporated

$12.06B-16.3%2.7%

$4.23B-1.2%6.9%

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Revelation Biosciences, Inc. (REVB) reported net income of −$8.9M for FY2025 (fiscal year ending 2025-12-31), up 40.7% year-over-year. The net profit margin was — — meaning the company kept $— of every dollar of revenue as profit.

Revelation Biosciences, Inc. has not yet achieved annual profitability based on available data (7 fiscal years). The company has reported net losses across all available periods.

Revelation Biosciences, Inc.'s net profit margin was — for FY2025, based on the latest annual results.

Investors sometimes search for "Revelation Biosciences, Inc. net worth" — the company's market capitalization is a separate figure from REVB net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

REVB net income · 4 questions

Revelation Biosciences, Inc. is not currently profitable on an annual basis. The company reported a net loss of $8.9M for FY2025.

is REVB profitabledoes REVB make a profitREVB profitabilityREVB profitable company

▸ Source: FMP /income-statement · GAAP · Revelation Biosciences, Inc. · Revelation Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026